Literature DB >> 3547005

Neurological manifestations and toxicities of the antituberculosis drugs. A review.

M R Holdiness.   

Abstract

The neurological manifestations and toxicities of 12 antituberculosis drugs [isoniazid, rifampicin (rifampin), ethambutol, p-aminosalicylic acid, pyrazinamide, streptomycin, kanamycin, ethionamide, cycloserine, capreomycin, viomycin and thiacetazone] are reviewed. Their effects upon the central nervous system, cranial nerves, peripheral nerves and the neuromuscular junction are examined, and drug interactions of neurological concern are briefly discussed. Isoniazid is well known to increase the concentrations of gamma-aminobutyric acid in neural tissues. Although conflicting data have been published, isoniazid may play a limited future role in reducing the degree of adventitious movements noted in certain neurological diseases such as multiple sclerosis, spasmodic torticollis, and other segmental dystonic syndromes. With rifampicin neurological complications have been observed infrequently. Rifampicin penetrates into the CSF and has been shown to have useful activity against various micro-organisms in the CSF, including certain viruses; however, contrary to earlier suggestions, it appears to have no role in the treatment of subacute sclerosing panencephalitis. A number of studies have indicated that isoniazid is associated with a large number of accidental and intentional poisonings. The highest incidence has been observed with Southwestern American Indians in which this agent was involved in 7% of all suicide attempts and 19% of the suicide deaths. Degeneration of the optic chiasma and nerve is a well-known adverse effect of ethambutol; toxicity is manifested by impairment of visual acuity, marked loss of colour discrimination, constricted visual fields, and central and peripheral scotoma. Ototoxicity is a well known problem caused by streptomycin, kanamycin, capreomycin and viomycin. The use of streptomycin in pregnant mothers is associated with congenital deafness in newborns in certain cases. The aminoglycoside antibiotics are also associated with flaccid paralysis following neuromuscular blockade. Adverse reactions to cycloserine are mainly dose-related with neurological and psychiatric syndromes noted in up to 50% of patients. Recent data indicate that isoniazid, rifampicin, ethambutol, pyrazinamide, streptomycin, kanamycin, ethionamide, and cycloserine appear in measurable quantities in the cerebrospinal fluid. Five of these compounds (isoniazid, rifampicin, ethambutol, kanamycin, cycloserine) pass to some degree through non-inflamed meninges. Other than discontinuation of the therapeutic regimen and general supportive measures, very few methods are described in the literature for treatment of acute intoxications with antituberculosis drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3547005     DOI: 10.1007/BF03259859

Source DB:  PubMed          Journal:  Med Toxicol        ISSN: 0112-5966


  162 in total

1.  Optic atrophy after administration of isoniazid with P.A.S.

Authors:  P H SUTTON; P H BEATTIE
Journal:  Lancet       Date:  1955-03-26       Impact factor: 79.321

2.  Viomycin therapy in human tuberculosis.

Authors:  H G SCHAFFELD; B GARTHWAITE; J B AMBERSON
Journal:  Am Rev Tuberc       Date:  1954-04

3.  A case of irreversible bilateral optic damage after ethambutol therapy.

Authors:  G Boman; B Calissendorff
Journal:  Scand J Respir Dis       Date:  1974

4.  [Streptomycin therapy during pregnancy and its effect on the hearing of the offspring].

Authors:  G Ganguin; E Rempt
Journal:  Z Laryngol Rhinol Otol       Date:  1970-08

5.  The ocular toxicity of ethambutol and its relation to dose.

Authors:  J E Leibold
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

Review 6.  Antibiotics and neuromuscular function.

Authors:  M D Sokoll; S D Gergis
Journal:  Anesthesiology       Date:  1981-08       Impact factor: 7.892

7.  Isoniazid toxicity. Pyridoxine controlled seizures in a dialysis patient.

Authors:  E R Wood
Journal:  J Kans Med Soc       Date:  1981-12

8.  Depression of prahydroxylation of diphenylhydantoin by antituberculosis chemotherapy.

Authors:  H Kutt; W Winters; F H McDowell
Journal:  Neurology       Date:  1966-06       Impact factor: 9.910

9.  Secondary mania: manic syndromes associated with antecedent physical illness or drugs.

Authors:  C Krauthammer; G L Klerman
Journal:  Arch Gen Psychiatry       Date:  1978-11

10.  Effect of L-glutamine and isoniazid on torticollis and segmental dystonia.

Authors:  J Korein; A Lieberman; M Kupersmith; L Levidow
Journal:  Ann Neurol       Date:  1981-09       Impact factor: 10.422

View more
  13 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced seizures.

Authors:  G Zaccara; G C Muscas; A Messori
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

Review 2.  Transplacental pharmacokinetics of the antituberculosis drugs.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

3.  Neurological and Psychiatric Adverse Effects of Antimicrobials.

Authors:  Madison K Bangert; Rodrigo Hasbun
Journal:  CNS Drugs       Date:  2019-08       Impact factor: 5.749

Review 4.  Nervous system effects of antituberculosis therapy.

Authors:  Joseph S Kass; Wayne X Shandera
Journal:  CNS Drugs       Date:  2010-08       Impact factor: 5.749

Review 5.  Management of tuberculosis meningitis.

Authors:  M R Holdiness
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

6.  Oxidative activation of thiacetazone by the Mycobacterium tuberculosis flavin monooxygenase EtaA and human FMO1 and FMO3.

Authors:  Lian Qian; Paul R Ortiz de Montellano
Journal:  Chem Res Toxicol       Date:  2006-03       Impact factor: 3.739

Review 7.  A review of the Redman syndrome and rifampicin overdosage.

Authors:  M R Holdiness
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

8.  Synthetic EthR inhibitors boost antituberculous activity of ethionamide.

Authors:  Nicolas Willand; Bertrand Dirié; Xavier Carette; Pablo Bifani; Amit Singhal; Matthieu Desroses; Florence Leroux; Eve Willery; Vanessa Mathys; Rebecca Déprez-Poulain; Guy Delcroix; Frédéric Frénois; Marc Aumercier; Camille Locht; Vincent Villeret; Benoit Déprez; Alain R Baulard
Journal:  Nat Med       Date:  2009-05-03       Impact factor: 53.440

Review 9.  Clinical pharmacokinetics of clofazimine. A review.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

10.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.